INTRODUCTION

Wi l s on d i s e a s e ( W D )
is a rare inherited copper storage disorder caused by insufficient copper excretion into the bile due to mutations in the copper-transporting P-type ATPase gene ATP7B [1, 2] . The subsequent copper accumulation primarily in the liver and brain leads to hepatic and neurologic manifestations of the disease [3] . Hepatic i nvolve me nt of W D c an present as chronic liver disease or in 5-10% of cases as acute liver failure (ALF) [4] . With lifelong medical treatment using chelators (D-pencillamine, trientine) or zinc salts [4] prolonged survival has become the norm [5] .
In WD, copper delivery to cuproenzymes such as ceruloplasmin is impaired [1, [6] [7] [8] . The resulting low plasma levels of ceruloplasmin have been associated with changes in coagulation in humans by influencing the coagulation pathway involving activated protein C (APC), factor V and factor VIII [9] . Ripoll et al. suggested that high levels of ceruloplasmin might be associated with a higher risk for venous thrombosis due to reduced sensitivity for APC [9] .
Activated factor V has metal binding sites for copper homologous to the human ceruloplasmin A domain and factor VIII. Copper binding is important for proper non-covalent association of the subunits of activated factor V [10] .
Similarly, factor VIII structure and function is dependent on copper binding as demonstrated previously [11] [12] [13] [14] .
Von Willebrand factor (vWF) facilitates proper assembly and stabilization of factor VIII [15, 16] . The D domains of the vWF are extremely rich in cystein, similar to those of the copper binding metallothionins [17] . Investigation of coagulation factors in WD patients has been very limited so far: low levels of factor II, V, VII, X and lower prothrombin indices have been reported in a small group of 9 Wilson patients at the time of diagnosis with normalization under therapy [18] .
Owen et al. analyzed platelet function and coagulation in 16 Wilson patients of whom 5 described easy bruising [19] . Three of these 5 patients had mild thrombocytopenia. No significant changes were found regarding bleeding times, platelet retention and prothrombin consumption. However, 15 of the 16 patients had abnormalities of platelet aggregation. Cohen et al. also described abnormal platelet function in WD [20] .
Von Willebrand factor has been discovered and established as a new non-invasive predictor of portal hypertension, hepatic decompensation and mortality in patients with liver cirrhosis. High levels of vWF were associated with poor outcome in these patients. High levels of vWF antigen are thought to play a role in the hypercoagulable state of cirrhotic patients [21, 22] .
The aim of the current study was the analysis of coagulation factors in patients with WD as copper status has been suggested to influence coagulation factors in various ways.
METHODS
Data were obtained in terms of a prospective cross sectional cohort study. The study was approved a priori by the local Ethics Committee and is in compliance with the Helsinki Declaration. Written informed consent was obtained from each patient.
All patients included had a confirmed diagnosis of WD [6, 7] and were 18 years or older. Patient history was as described previously [4] . Patients receiving anticoagulant co-medication and patients under anti-platelet aggregation therapy as well as patients after liver transplantation were excluded from the study.
The following coagulation parameters were determined out of peripheral venous blood in a standard laboratory setting at Heidelberg University Hospital in all patients: full blood count, INR, partial thromboplastin time (PTT), clotting factors II, V, VII, VIII, IX, X, XI, XII, XIII, vWF/-antigen, fibrinogen, antithrombin III, protein S, protein C, APC resistance. Platelet function was not analyzed in this study. The results of the blood tests were integrated into the Heidelberg WD patient data bank.
Statistical analysis
Statistical analyses were performed with PASW statics 18 by IBM™. Comparisons of quantitative variables were performed by the unpaired Mann-Whitney-Test. Kruskal-Wallis tests were used in the presence of more than two subgroups. Data are presented as means ± SD. A p value < 0.05 was considered as statistically significant.
RESULTS
Patients' characteristics
The characteristics of the 100 WD patients included in the study are given in Table I : 65% of the study group initially presented with hepatic symptoms; 6% of the patients had liver cirrhosis Child B or C; 52% of the patients examined were under D-pencillamine therapy, 25% under trientine medication and 20% received zinc therapy. Clinical and laboratory parameters of the study group are presented in Table II . For the whole study group the changes characteristic for WD in serum copper and ceruloplasmin levels were out of the normal range. There were no statistically significant differences when analyzing the male and female subgroup for all the items shown in Table II .
Coagulation parameters
Factor VIII levels (132.9%, normal range: 80-120%) and vWF antigen levels (145%, normal range: 70-100%) were the only coagulation factors elevated above the normal range within the study group. All other assessed coagulation parameters showed levels within the normal range (Table III) for the whole study population as well as for the male and female subgroups. Von Willebrand factor (%) was the only parameter differing significantly (p=0.011) in the gender based subgroup analysis. However, single patients obviously had coagulation parameters out of the normal range as seen through the min-max values given in Table III . For example, single patients had PTT prolongations, decreased protein C levels or decreased levels of coagulation factors II, VII, X suggestive for impairment of liver function.
Subgroup analysis by liver function
Subgroups were analyzed by liver function in terms of Model for End stage Liver Disease (MELD) score. In patients with a MELD score > 8 significantly decreased levels of the factors II, V, VII and X were noticed. The other coagulation parameters showed no significant differences (Table IV) 
Subgroup analysis by clinical presentation
A subgroup analysis based on clinical presentation related to the involved organ was performed. The subgroup characteristics and variations in coagulation parameters are given in Tables Va/Vb. As expected, the subgroups with hepatic and mixed hepatic/neurologic presentation had significantly elevated liver function tests (ALT, AST, bilirubin, MELD scores). There were no significant differences between the subgroups when analyzing the parameters relevant for blood coagulation. The hepatic and mixed subgroups had a trend of lower values for the liver derived coagulation parameters (factor II, VII, X, Quick, PTT), however not reaching statistical significance.
Subgroup analysis by treatment
Influence of the medical regimens used for WD on the coagulation markers were studied by subgroup analysis, based on the medical treatment the patients were receiving at the time of enrolment in the present study. Data of the three patients with combination treatments (Table I) are not shown for better readability of the table (see supplementary Table I ). There were minor, however significant, alterations within the treatment groups suggesting therapy-specific alterations of coagulation markers by the treatment of WD: trientine was significantly associated with lower levels of AT3, Quick, factor II and factor VII. Furthermore, it was associated with elevated levels of vWF and vWF antigen. Zinc was associated with lower factor VIII levels and prolonged PTT.
DISCUSSION
Copper has been suggested to play an important role as a structural and functional component for coagulation factors previously [9] [10] [11] [12] [13] [14] [15] [16] . Only limited data are currently available on the detailed alterations of coagulation factors caused by WD and by WD treatment regimens [18] [19] [20] . The aim of the current study was to investigate alterations in the coagulation system in WD patients.
The study involved 100 WD patients. Our expectation, based on previous reports [18] [19] [20] , was to find altered parameters of coagulation factors. Despite the fact that previous studies revealed alterations in thrombocyte function in WD patients [20] , we focused on serum coagulation markers and platelet counts assessed in clinical routine follow up of WD patients. This represents a limitation of our study.
No significant changes of the coagulation system could be found when analyzing the whole study group, the subgroups of male or female patients and the subgroups defined by clinical WD presentation.
Overall, factor VIII and factor V showed normal activity levels. This rules out a general problem of copper acquisition of these two proteins in WD, as suggested previously due to the homologies of factor V and VIII to ceruloplasmin, which is supplied with copper through the WD protein ATP7B. This is in line with the personal communication of Brewer in the study of Tagliavacca et al. [12] . Tagliavacca et al. discussed the potential mechanism of copper delivery to factor VIII within the secretory pathway. In this study, unpublished results of Brewer are reported: the analysis of plasma factor VIII levels in 10 patients affected by WD and ceruloplasmin deficiency demonstrated normal levels. These observations are seen as indications that factor VIII and ceruloplasmin exhibit different requirements for copper delivery within the secretory pathway. Involvement of the Wilson protein in copper delivery to factor VIII could therefore be less likely. However, it can be speculated if factor V and VIII receive their copper directly or indirectly through the Menkes protein (ATP7A) or independent of these ATPases. Remarkably, we found mean factor VIII concentrations above the normal range in our study cohort. It is known that a great proportion of factor VIII is produced by the vascular endothelium and not by the liver. Therefore, one might speculate that increased factor VIII levels might be a compensatory mechanism in case of impaired hepatic production of coagulation factors. This was shown in patients with acute liver failure in a study by Argawal et al. [23] , and also in a large animal model where not only increased systemic factor VIII levels but also prolonged factor VIII half-life and factor VIII production in the spleen and kidney were observed in anhepatic pigs [24] .
We evaluated the influence of different treatment regimens on the coagulation parameters. Treatment with zinc was associated with lower factor VIII levels and prolonged PTT. It could be speculated that the high concentrations of zinc specifically inhibit factor VIII formation, copper delivery or function. Treatment with trientine was significantly associated with lower factors II, VII, Quick and AT3 as well as elevated levels of vWF and vWF antigen. The significantly lower Quick score in the trientine treatment group indicates that patients in this group had more severe liver disease. This could explain the observed changes in factors II and VII. Regarding the elevated vWF and vWF antigen, a possible explanation could be the presence of portal hypertension, which is associated with impaired liver function. Portal hypertension is a condition that can be regarded as an endothelial stress. Since a great proportion of vWF and vWF antigen are located in the endothelium, elevated serum concentrations of these proteins in patients treated with trientine could be a compensatory mechanism.
Moreover, we analyzed the influence of impaired liver function on coagulation parameters. Not surprisingly, we detected significantly decreased factors II, V, VII and X indicating their impaired hepatic production. Nonetheless, all these factors were within normal laboratory range.
Due to the availability of effective medical treatment for WD since the 1950s, WD patients are now entering the elderly groups where anticoagulation therapy is needed more commonly, e.g. acetylsalicylic acid, clopidogrel, ticagrelor etc. for coronary heart disease, peripheral arterial disease or after stroke, or substances such as warfarin, rivaroxaban, dabigatran and others for atrial fibrillation or after trombembolic events. Due to the lack of detectable coagulation changes, one would suggest that WD patients could receive anticoagulant medication as the normal population based on the results of the present study.
CONCLUSION
Our study shows an unimpaired coagulation system in WD with only minor changes associated with certain treatment regimens. The current available data suggest that changes in coagulation in WD patients are not disease specific.
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